Evidence map›Paper›PMID 41472272›Full record

ArticleViruses2025

Hepatitis C Virus Infection in Mongolia: Updated Provincial Data on Prevalence, Genotype Distribution, and Age-Specific Risk Factors.

Amgalan Byambasuren, Myagmarjaltsan Baatarzorigt, Munkhtuya Otgon, Byambasuren Bat-Amgalan, Mandakhnaran Purevkhuu, Naranzul Nyamsuren, Enkh-Amar Ayush, Dashchirev Munkh-Orshikh, Khurelbaatar Nyamdavaa, Oidov Baatarkhuu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Amgalan ByambasurenDepartment of Health Research, Graduate School, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia.
Myagmarjaltsan BaatarzorigtGeneral Hospital, Tsetserleg 6519, Mongolia.
Munkhtuya OtgonSoum Health Center of the Arkhangai Province, Ulaanbaatar 15141, Mongolia.
Byambasuren Bat-AmgalanDepartment of Administration, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia.
Mandakhnaran PurevkhuuDepartment of Administration, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia.
Naranzul NyamsurenDepartment of Infectious Diseases, School of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia.
Enkh-Amar AyushDepartment of Gastroenterology, School of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia.
Dashchirev Munkh-OrshikhNational Cancer Center, Ulaanbaatar 13370, Mongolia.
Khurelbaatar NyamdavaaDepartment of Administration, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia.
Oidov BaatarkhuuDepartment of Infectious Diseases, School of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia.ORCID 0000-0002-0769-3693

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(1) Background: Mongolia has historically reported one of the highest hepatitis C virus (HCV) prevalence rates globally, with past national estimates exceeding 15%, making HCV infection a major public health priority. This study aimed to assess the prevalence, genotype distribution, and risk factors of HCV infection among residents of Arkhangai Province. (2) Methods: This population-based cross-sectional study was conducted in 2022 including 2304 individuals aged 0-80 years. Serum samples were tested for anti-HCV antibodies using ELISA and for HCV RNA using PCR. Positive samples were genotyped, and demographic and exposure data were analyzed using logistic regression to identify independent risk factors. (3) Results: The prevalence of anti-HCV antibodies was 12.0%, and HCV RNA positivity was 7.16%. Infection increased significantly with age (

Indexed as

GenotypeHepacivirusHepatitis CAdolescentAdultAgedAged, 80 and overAge FactorsChildChild, PreschoolCross-Sectional StudiesFemaleHepatitis C AntibodiesHumansInfantInfant, NewbornHepatitis C AntibodiesRNA, Viralcupping therapygenotype 1bhepatitis C virusMongoliaprevalencerisk factorsunsafe injection

Identifiers

PMID41472272
PMCPMC12737555

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.